Amicus Therapeutics: 2 Potential Blockbusters Make This Stock Worth Considering
Seeking Alpha - Article · 06/18 13:45
BTIG Initiates Coverage On Amicus Therapeutics with Buy Rating, Announces Price Target of $19
BTIG analyst Dae Gon Ha initiates coverage on Amicus Therapeutics (NASDAQ:FOLD) with a Buy rating and announces Price Target of $19.
Benzinga · 06/17 10:25
Protalix Undervalued Due To Ghost Of Shire, Upside On Fabry Approval Significant
Seeking Alpha - Article · 06/09 12:23
Amicus Therapeutics, Inc. (FOLD): Hedge Funds Folding Their Hands
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are
Insider Monkey · 06/08 07:38
Why Is Amicus Therapeutics (FOLD) Up 10.9% Since Last Earnings Report?
Zacks · 06/06 16:31
Amicus Therapeutics to Present at the Goldman Sachs 41st Annual Global Healthcare Conference
CRANBURY, N.J., June 04, 2020 -- Amicus Therapeutics (Nasdaq: FOLD) today announced that John F. Crowley, Chairman and Chief Executive Officer, will participate in a fireside.